New 'Living Drug' trial offers hope for Tough-to-Treat cancers
NCT ID NCT07179692
Summary
This early-stage study is testing the safety and early effectiveness of a new CAR-T cell therapy for people with advanced solid tumors that have a specific marker called CEA. The therapy involves collecting a patient's own immune cells, modifying them in a lab to better target cancer, and then infusing them back into the body. The study will test different doses and methods of infusion to find the best approach for patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.